ID   A375-RMR SCH 0.25
AC   CVCL_B3PJ
SY   A375 SKIN CJ3; A375-CJ3
DR   cancercelllines; CVCL_B3PJ
DR   Cell_Model_Passport; SIDM01936
DR   DepMap; ACH-002003
DR   Wikidata; Q110429848
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   From: Johannessen C.M.; Broad Institute of MIT and Harvard; Harvard; USA.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; GSK2118436).
CC   Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist; GSK1120212).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): DepMap
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,14
ST   D16S539: 9
ST   D18S51: 12,17
ST   D21S11: 29,30
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 9
ST   D8S1179: 11,14
ST   FGA: 22,23
ST   Penta D: 9,15
ST   Penta E: 10,12
ST   TH01: 8
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A1VP ! A375-RMR
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 16-12-21; Last updated: 05-10-23; Version: 7
//